Fertility warning
This medicine may affect fertility.
Leaflet ERLOTINIB MYLAN 100mg film-coated tablets
- Product code:
- W68228001
- Quantity:
- 30
- Indicated for:
- non-small cell lung cancer; pancreatic cancer
- Route of administration:
- oral
- Substance:
- erlotinib (tyrosine kinase inhibitor)
- ATC
- L01EB02 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
Precautions:
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Erlotinib is a medication used in the treatment of certain types of lung cancer and advanced pancreatic cancer. It works by blocking a protein involved in the growth and multiplication of cancer cells, thus helping to slow disease progression.
Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.
Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.
Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.
Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.
Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.
Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.
General data about ERLOTINIB MYLAN 100mg
- Substance:
- erlotinib
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W68228001
- Concentration:
- 100mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 30
- Product type:
- Generic medicine
- Price:
- 1942.18 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for erlotinib
- 100mg
- 150mg
- 25mg
- 50mg